Intelligent Bio Solutions Secures Bouygues UK Deal for Fingerprint Drug Testing
Event summary
- Intelligent Bio Solutions (INBS) partners with Bouygues UK for fingerprint drug testing across 13 UK project sites.
- Bouygues UK transitions from third-party testing to INBS's in-house solution, citing hygiene, efficiency, and cost savings.
- ROI analysis validated the economic benefits of the technology for large-scale industrial applications.
- Bouygues Construction reported €10.3 billion turnover in 2024, operating in over 50 countries.
The big picture
This partnership marks a strategic shift from third-party to in-house drug testing solutions in the construction industry, driven by cost savings and operational efficiency. The deal highlights the growing demand for non-invasive, rapid testing technologies in safety-critical sectors. With Bouygues Construction's global footprint, INBS has a significant opportunity to expand its market reach.
What we're watching
- Scale Potential
- Whether INBS can replicate this success across Bouygues Construction's global operations.
- Industry Adoption
- The pace at which other safety-critical industries adopt INBS's fingerprint testing technology.
- Competitive Dynamics
- How traditional third-party testing providers respond to INBS's in-house solution model.
Related topics